nach oben

Erschienen in:

29.01.2021 | Original Article

Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(−) breast cancer receiving salvage treatment with everolimus/exemestane

verfasst von: Maria Spiliotaki, Galatea Kallergi, Christos Nikolaou, Nikolaos Xenidis, Eleni Politaki, Stella Apostolaki, Nefeli Georgoulia, Filippos Koinis, Nikolaos Tsoukalas, Dora Hatzidaki, Athanasios Kotsakis, Vassilis Georgoulias

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Detection of CTCs represents a poor prognostic factor in patients with early and metastatic breast cancer (mBC) and treatment with everolimus–exemestane (E/E) is an established effective treatment in hormone receptor-positive/HER2-negative mBC patients. The effect of E/E on CTCs in mBC patients was prospectively investigated.

Methods

CTCs from 50 pre-treated patients with mBC receiving E/E were analyzed using the CellSearch (CS) platform and triple immunofluorescence (IF) staining for cytokeratin, M30 and Ki67 expression to assess their proliferative and apoptotic status.

Results

CTCs (by CS) were detected in 64% of patients before treatment and E/E administration resulted in their decreased prevalence [(n = 18; 36%, p = 0.004) and (n = 7; 19.4%, p = 0.019) post-1st and post-3rd treatment cycle, respectively] whereas it was significantly increased at disease progression (PD: 61%) compared to post-1st and post-3rd cycle (p = 0.049 and p = 0.021, respectively). Ki67-positive CTCs were detected in 60%, 60%, 17% and 50% of patients before treatment, post-1st, post-3rd cycle and at PD, respectively, while the opposite was observed for M30-positive CTCs (0% at baseline, 10% after the 1st cycle, 50% after the 3rd cycle and 0% at PD). The detection of even ≥ 1 CTC/5 ml after one cycle was associated with decreased PFS (3.3 vs 9.0 months, p = 0.025) whereas the detection of even ≥ 2 CTCs at PD was associated with decreased OS (32.4 vs 19.5 months; p = 0.009).

Conclusions

The combination of E/E resulted in early elimination of proliferating CTCs in mBC patients and this effect was associated with a favorable clinical outcome.

Nur mit Berechtigung zugänglich

Johnston SR (2015) Enhancing endocrine therapy for hormone receptor-positive advanced breast cancer: cotargeting signaling pathways. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv212CrossRefPubMed

Miller TW, Balko JM, Arteaga CL (2011) Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 29(33):4452–4461. https://doi.org/10.1200/JCO.2010.34.4879CrossRef

Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6(9):729–734. https://doi.org/10.1038/nrc1974CrossRefPubMed

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM et al (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res Off J Am Assoc Cancer Res 10(23):8059–8067. https://doi.org/10.1158/1078-0432.CCR-04-0035CrossRef

Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O’Reilly T et al (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120(6):747–759. https://doi.org/10.1016/j.cell.2004.12.040CrossRefPubMed

Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R et al (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Can Res 64(1):252–261CrossRef

Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O’Reilly T, Evans DB et al (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 11(14):5319–5328. https://doi.org/10.1158/1078-0432.CCR-04-2402CrossRef

Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529. https://doi.org/10.1056/NEJMoa1109653CrossRefPubMed

Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y et al (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger. Ann Oncol Off J Eur Soc Med Oncol 25(12):2357–2362. https://doi.org/10.1093/annonc/mdu456CrossRef

10.

Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V et al (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544. https://doi.org/10.1038/nbt.2576CrossRefPubMed

11.

Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D et al (2002) Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res Off J Am Assoc Cancer Res 8(7):2073–2084

12.

Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791. https://doi.org/10.1056/NEJMoa040766CrossRefPubMed

13.

Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC et al (2006) Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 12(21):6403–6409. https://doi.org/10.1158/1078-0432.CCR-05-1769CrossRef

14.

Welter L, Xu L, McKinley D, Dago AE, KP R, Restrepo-Vassalli S et al (2020) Treatment response and tumor evolution: Lessons from an extended series of multi-analyte liquid biopsies in a metastatic breast cancer patient. Cold Spring Harbor molecular case studies. https://doi.org/10.1101/mcs.a005819CrossRefPubMedPubMedCentral

15.

Agelaki S, Dragolia M, Markonanolaki H, Alkahtani S, Stournaras C, Georgoulias V et al (2017) Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients. Oncotarget 8(3):5309–5322. https://doi.org/10.18632/oncotarget.14144CrossRefPubMed

16.

Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, Mavroudis D et al (2015) Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. Breast Cancer Res BCR 17:113. https://doi.org/10.1186/s13058-015-0624-xCrossRefPubMed

17.

Kallergi G, Aggouraki D, Zacharopoulou N, Stournaras C, Georgoulias V, Martin SS (2018) Evaluation of alpha-tubulin, detyrosinated alpha-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements. Breast Cancer Res BCR 20(1):67. https://doi.org/10.1186/s13058-018-0993-zCrossRefPubMed

18.

Kallergi G, Hoffmann O, Bittner AK, Papadimitriou L, Katsarou SD, Zacharopoulou N et al (2020) CXCR4 and JUNB double-positive disseminated tumor cells are detected frequently in breast cancer patients at primary diagnosis. Ther Adv Med Oncol 12:1758835919895754. https://doi.org/10.1177/1758835919895754CrossRefPubMedPubMedCentral

19.

Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S (2011) Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res BCR 13(3):R59. https://doi.org/10.1186/bcr2896CrossRefPubMed

20.

Kallergi G, Konstantinidis G, Markomanolaki H, Papadaki MA, Mavroudis D, Stournaras C et al (2013) Apoptotic circulating tumor cells in early and metastatic breast cancer patients. Mol Cancer Ther 12(9):1886–1895. https://doi.org/10.1158/1535-7163.MCT-12-1167CrossRefPubMed

21.

Spiliotaki M, Mavroudis D, Kapranou K, Markomanolaki H, Kallergi G, Koinis F et al (2014) Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. Breast Cancer Res BCR 16(6):485. https://doi.org/10.1186/s13058-014-0485-8CrossRefPubMed

22.

Deutsch TM, Riethdorf S, Nees J, Hartkopf AD, Schonfisch B, Domschke C et al (2016) Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. Breast Cancer Res Treat 160(2):277–290. https://doi.org/10.1007/s10549-016-3997-3CrossRefPubMed

23.

Hartkopf AD, Wagner P, Wallwiener D, Fehm T, Rothmund R (2011) Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res 31(3):979–984PubMed

24.

Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC et al (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res Off J Am Assoc Cancer Res 12(14 Pt 1):4218–4224. https://doi.org/10.1158/1078-0432.CCR-05-2821CrossRef

25.

Jansson S, Bendahl PO, Larsson AM, Aaltonen KE, Ryden L (2016) Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. BMC cancer 16:433. https://doi.org/10.1186/s12885-016-2406-yCrossRefPubMedPubMedCentral

26.

Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627–644. https://doi.org/10.1038/nrd2926CrossRefPubMedPubMedCentral

27.

Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M et al (2012) High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol Off J Eur Soc Med Oncol 23(3):618–624. https://doi.org/10.1093/annonc/mdr263CrossRef

28.

Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G et al (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol Off J Am Soc Clin Oncol 32(31):3483–3489. https://doi.org/10.1200/JCO.2014.56.2561CrossRef

29.

Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K et al (2013) The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 137(2):503–510. https://doi.org/10.1007/s10549-012-2382-0CrossRefPubMed

30.

Ignatiadis M, Rothe F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C et al (2011) HER2-positive circulating tumor cells in breast cancer. PLoS ONE 6(1):e15624. https://doi.org/10.1371/journal.pone.0015624CrossRefPubMedPubMedCentral

31.

Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH et al (2002) Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360(9334):683–689. https://doi.org/10.1016/S0140-6736(02)09838-0CrossRefPubMed

32.

Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N et al (2013) Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. Br J Cancer 108(3):549–556. https://doi.org/10.1038/bjc.2012.597CrossRefPubMedPubMedCentral

33.

Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M et al (2007) Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 25(33):5194–5202. https://doi.org/10.1200/JCO.2007.11.7762CrossRef

34.

Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M et al (2008) Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 14(9):2593–2600. https://doi.org/10.1158/1078-0432.CCR-07-4758CrossRef

35.

Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S et al (2009) Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(13):2177–2184. https://doi.org/10.1200/JCO.2008.18.0497CrossRef

36.

Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K et al (2011) Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Res BCR 13(3):R60. https://doi.org/10.1186/bcr2897CrossRefPubMed

37.

Tang D, Lahti JM, Kidd VJ (2000) Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis. J Biol Chem 275(13):9303–9307CrossRef

38.

Ueno T, Toi M, Linder S (2005) Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother = Biomedecine & pharmacotherapie 59(Suppl 2):S359–S362CrossRef

39.

Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res Off J Am Assoc Cancer Res 10(20):6897–6904. https://doi.org/10.1158/1078-0432.CCR-04-0378CrossRef

40.

Shiomi-Mouri Y, Kousaka J, Ando T, Tetsuka R, Nakano S, Yoshida M et al (2016) Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer. Breast Cancer 23(1):120–127. https://doi.org/10.1007/s12282-014-0539-xCrossRefPubMed

41.

Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F et al (2017) A comparison of three methods for the detection of circulating tumor cells in patients with early and metastatic breast cancer. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 44(2):594–606. https://doi.org/10.1159/000485115CrossRef

42.

Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z et al (2006) p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res BCR 8(4):R48. https://doi.org/10.1186/bcr1536CrossRefPubMed

43.

Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M et al (2009) Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 101(1):61–66. https://doi.org/10.1093/jnci/djn419CrossRefPubMedPubMedCentral

44.

Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S (2009) Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res BCR 11(4):R46. https://doi.org/10.1186/bcr2333CrossRefPubMed

Titel: Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(−) breast cancer receiving salvage treatment with everolimus/exemestane
verfasst von: Maria Spiliotaki
Galatea Kallergi
Christos Nikolaou
Nikolaos Xenidis
Eleni Politaki
Stella Apostolaki
Nefeli Georgoulia
Filippos Koinis
Nikolaos Tsoukalas
Dora Hatzidaki
Athanasios Kotsakis
Vassilis Georgoulias
Publikationsdatum: 29.01.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2021
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-020-04227-5

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(−) breast cancer receiving salvage treatment with everolimus/exemestane

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1–XPF-mediated DNA repair

Disulfiram: a novel repurposed drug for cancer therapy

Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer

Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types

Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients

Tumor microenvironment promotes breast cancer chemoresistance

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie